Clinical Trials Logo

Multi-antibiotic Resistance clinical trials

View clinical trials related to Multi-antibiotic Resistance.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06370299 Not yet recruiting - Clinical trials for Multi-antibiotic Resistance

Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient

Start date: June 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to evaluate the screening for multidrug resistant bacteria in patients admitted to hospitals in Scania. The main questions it aims to answer are: - admission rates after screening - 30-day and one-year mortality after screening Participants will be evaluated for positive screening results with following multidrug resistant gram negative bacilli: ESBL producing Enterobacterales, Carbapenemase producing Enterobacterales, Carbapenem resistant P.aeruginosa and carbapenem resistant Acinetobacter baumannii. Researchers will compare patients with positive and negative screening results to see, if the relative risks in the two groups differ in admission rates and mortality.

NCT ID: NCT05791396 Not yet recruiting - Clinical trials for Enterobacteriaceae Infections

FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae

FMT_CRE
Start date: April 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Antibiotic resistance (AR) is a critical public health threat and one of the greatest challenges of the 21st century. In an estimate of 2019, nearly 700.000 infections and 33.000 attributable deaths from multi-drug-resistant bacteria (MDRB) have occurred in Europe in 2015. The gastrointestinal tract is a large reservoir for MDRB, and the gut microbiota can harbor a collection of AR genes, called gut resistome. Preliminary nonrandomized evidence suggests that fecal microbiota transplant (FMT) could be a promising treatment option to eradicate MDRB, but established evidence, as well as mechanisms that underpin this therapeutic pathway, are still unavailable. Leveraging our expertise in FMT (OU1), microbiome (OU2) and MDRB (OU3), we aim to evaluate the efficacy of FMT (from donors with limited presence of AR genes) in eradicating intestinal MDRB through a randomized controlled trial and identifying microbial features that are associated with clinical efficacy and clearance of AR genes